Great Fight Scene (SPOILERISH)

Anybody seen Nobody? I feel like we’ve talked about this one.

Hutch is a nobody. As an overlooked and underestimated father and husband, he takes life’s indignities on the chin and never rocks the boat. But when his daughter loses her beloved kittycat bracelet in a robbery, Hutch hits a boiling point no one knew he had. What happens when a pushover finally pushes back? Hutch flips from regular dad to fearless fighter by taking his enemies on a wild ride of explosive revenge. The writer of John Wick showcases Emmy® winner Bob Odenkirk (Better Call Saul) as fans have never seen him before: an average family man who becomes a lethal vigilante unlike any ordinary action hero.

Yep

One of the measures of a great song is relatability. This one’s got it in spades.

Heavy Meta

I think I’ve posted this guy’s stuff before, but maybe not. Although he usually does superheroes or Star Wars characters, he’s still sickeningly talented.

Come To Butthead

First half of season 4 coming January 21st. All episodes, you may ask? I don’t know, I might very well answer.

Bring Me the Head of Charlie Brown

Charlie Brown is on the run from the Peanuts Gang after the Great Pumpkin puts a bounty on his head. Animated student short by Jim Reardon, who later worked on The Simpsons (1990–2004) – director, supervising director, storyboard consultant; WALL-E (2008) – screenwriter, story supervisor; Wreck-It Ralph (2012) – writer, head of story; and Zootopia (2016) – writer, co-head of story.

Word

A recent letter to the WSJ in response to a Theranos story:

I am a former biotech analyst. Several years ago, the chairman of a client company told me he had seen an interview with Elizabeth Holmes and thought she was terrific and his company would be interested in working with her. He wanted to know what I thought.

Here is what I did: I went to the Theranos website and looked at the management and board of directors. I immediately noticed two red flags: First, the lack of relevant experience in the CEO’s bio, and second, the board appeared to be decorated with famous names unrelated to Theranos’s business.

Next, I called the company and introduced myself to the person who answered the phone. I explained the reason for my call and that I would like to speak to Ms. Holmes or leave her a message. I was told that there was no mechanism by which I could do that or anyone else with whom I could speak. Red flag No. 3.

It took me 10 minutes and cost my client zero dollars. Any life-sciences analyst would have done exactly the same thing and undoubtedly reached a similar conclusion. No rocket science here. So pardon my skepticism at senior members of corporations testifying as to how much money they spent on due diligence. Perhaps it’s time for their shareholders to make a change.

Elizabeth Silverman

Prism Biomedical Research

New York